DexCom Slides as Investors Appear to Take Risk Off Ahead of Earnings

DexCom, Inc. (DXCM) is down 6.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver appears to be a mix of pre-earnings caution and profit-taking rather than a single clearly negative company announcement. This could be because investors are trimming exposure ahead of the company’s scheduled third-quarter report, while a newly disclosed insider stock sale may have added to the pressure even though it was made under a prearranged trading plan.

Details:

The company has scheduled its third-quarter 2026 earnings release and conference call for October 29, which can make trading more volatile as investors reposition before results.

A Form 4 filed on October 19 showed the EVP and chief legal and compliance officer sold 1,700 shares on October 15 at $85.48 each.

The filing states the transaction was executed under a Rule 10b5-1 plan adopted in November 2025, which suggests an automatic sale rather than a discretionary trade tied to fresh operating developments.

The company also publicized favorable clinical data last week, so today’s weakness does not appear tied to a newly announced setback and may instead reflect sentiment and short-term positioning.

Sources:

Dexcom Investor Relations, SEC, The New England Journal of Medicine

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$DXCM Insider Trading Activity

$DXCM insiders have traded $DXCM stock on the open market 25 times in the past 6 months. Of those trades, 0 have been purchases and 25 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:

KEVIN R SAYER (Executive Chair) has made 0 purchases and 6 sales selling 107,027 shares for an estimated $8,303,321.
MICHAEL JON BROWN (EVP Chief Legal Compliance Off) has made 0 purchases and 6 sales selling 10,200 shares for an estimated $801,261.
JON COLEMAN (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 9,823 shares for an estimated $722,628.
NICHOLAS AUGUSTINOS has made 0 purchases and 2 sales selling 8,089 shares for an estimated $679,768.
MARK G FOLETTA has made 0 purchases and 4 sales selling 8,000 shares for an estimated $627,179.
SADIE STERN (EVP Chief People & Culture Off) has made 0 purchases and 2 sales selling 5,130 shares for an estimated $447,643.
JEREME M SYLVAIN (EVP, Chief Financal Officer) sold 3,638 shares for an estimated $302,936
BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $150,079.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$DXCM Hedge Fund Activity

We have seen 526 institutional investors add shares of $DXCM stock to their portfolio, and 437 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

INVESCO LTD. added 9,693,273 shares (+173.3%) to their portfolio in Q2 2026, for an estimated $652,841,936
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 4,328,170 shares (+170.1%) to their portfolio in Q2 2026, for an estimated $291,502,249
D. E. SHAW & CO., INC. removed 3,932,889 shares (-99.9%) from their portfolio in Q2 2026, for an estimated $264,880,074
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,439,164 shares (+inf%) to their portfolio in Q2 2026, for an estimated $231,627,695
JPMORGAN CHASE & CO added 3,325,095 shares (+inf%) to their portfolio in Q2 2026, for an estimated $223,945,148
CASTLE HOOK PARTNERS LP added 3,068,495 shares (+382.7%) to their portfolio in Q2 2026, for an estimated $206,663,138
LOS ANGELES CAPITAL MANAGEMENT LLC removed 1,805,701 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $121,613,962

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$DXCM Congressional Stock Trading

Members of Congress have traded $DXCM stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:

SENATOR TINA SMITH has traded it 2 times. They made 0 purchases and 2 sales worth up to $500,000 on 05/07, 04/29.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$DXCM Price Targets

Multiple analysts have issued price targets for $DXCM recently. We have seen 9 analysts offer price targets for $DXCM in the last 6 months, with a median target of $85.0.

Here are some recent targets:

Kieran Ryan from Deutsche Bank set a target price of $86.0 on 06/23/2026
Matt O'Brien from Piper Sandler set a target price of $88.0 on 06/15/2026
Joshua Jennings from TD Cowen set a target price of $95.0 on 06/10/2026
Anthony Petrone from Mizuho set a target price of $85.0 on 06/09/2026
Jonathan Block from Stifel set a target price of $90.0 on 06/05/2026
Joanne Wuensch from Citigroup set a target price of $84.0 on 05/28/2026
Matt Miksic from Barclays set a target price of $64.0 on 05/18/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.